# TherapeuticsMD, Inc.: Form 10-Q for the period ended Jun 30, 2014

- Company: [TherapeuticsMD, Inc.](/companies/txmd.md) (CIK 25743)
- Form: 10-Q
- Filed: 2014-08-07
- Accepted by EDGAR: Aug 7, 2014, 16:44 ET
- Period: 2014-06-30
- Accession: 0001387131-14-002744
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/25743/000138713114002744/txmd-10q_063014.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/25743/000138713114002744/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2014-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2014-04-01 to 2014-06-30 | $3.8m | us-gaap:SalesRevenueNet |
| Revenue | 6 months, 2014-01-01 to 2014-06-30 | $6.6m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2014-04-01 to 2014-06-30 | $893.0k | us-gaap:CostOfGoodsSold |
| Cost of revenue | 6 months, 2014-01-01 to 2014-06-30 | $1.7m | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2014-04-01 to 2014-06-30 | $2.9m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2014-01-01 to 2014-06-30 | $4.9m | us-gaap:GrossProfit |
| Research and development | 3 months, 2014-04-01 to 2014-06-30 | $8.2m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2014-01-01 to 2014-06-30 | $14.1m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2014-04-01 to 2014-06-30 | $5.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2014-01-01 to 2014-06-30 | $10.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2014-04-01 to 2014-06-30 | −$10.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2014-01-01 to 2014-06-30 | −$19.9m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2014-04-01 to 2014-06-30 | −$10.9m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2014-01-01 to 2014-06-30 | −$20.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2014-04-01 to 2014-06-30 | −$0.07 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2014-01-01 to 2014-06-30 | −$0.14 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months, 2014-01-01 to 2014-06-30 | −$18.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2014-01-01 to 2014-06-30 | $31.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2014-06-30 | $35.6m | us-gaap:Cash |
| Current assets | at 2014-06-30 | $41.8m | us-gaap:AssetsCurrent |
| Total assets | at 2014-06-30 | $44.4m | us-gaap:Assets |
| Current liabilities | at 2014-06-30 | $6.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2014-06-30 | $6.9m | us-gaap:Liabilities |
| Shareholders' equity | at 2014-06-30 | $37.5m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/25743/000138713114002744/txmd-10q_063014.htm

Filed Aug 7, 2014.
Source: SEC EDGAR, the filing index for accession 0001387131-14-002744. Last ingested by Listed: Nov 14, 2026, 19:24 ET. No prices; not investment advice.
